InDex Pharmaceuticals AB, Stockholm. 608 likes · 17 talking about this · 3 were here. InDex Pharmaceuticals utvecklar cobitolimod, ett nytt läkemedel för

Köp aktier i InDex Pharmaceuticals Holding - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.

{{ chapter.num }}. {{ chapter.name }} Linc AB, 10,00%, 10,00%. Fjärde AP-Fonden, 7,50%, 7,50%. Avanza Pension, 3,70%, 3,70%. Staffan Rasjö, 3,50%, 3,50%. SEB Life International, 2,60%, 2,60 Carnegie acted as joint global co-ordinator in the SEK 533 million rights issue in InDex Pharmaceuticals.

Barron's also provides information on historical stock ratings, target InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. 1.816, 1,101, INDEX, AVA, NON, 17:13:33 InDex Pharmaceuticals Holding AB publishes prospectus in connection with a fully guaranteed rights issue Get today's InDex Pharmaceuticals Holding AB stock price and latest INDEX news as well as InDex Pharma real-time stock quotes, technical analysis, full InDex Pharmaceuticals AB, Stockholm. 608 likes · 17 talking about this · 3 were here. InDex Pharmaceuticals utvecklar cobitolimod, ett nytt läkemedel för InDex Pharmaceuticals Holding AB is a pharmaceutical development company focusing on immunological diseases where there is an unmet medical need for Among the main shareholders are SEB Venture Capital, Industrifonden and NeoMed Management. InDex Pharmaceuticals Holding AB (publ) is the parent Latest InDex Pharmaceuticals Holding AB (INDEX:STO) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile InDex Pharmaceuticals. INDEX.

9 december 2020 – Aktieägarna i InDex Pharmaceuticals Holding AB, org. nr 559067-6820 (nedan benämnt ”Bolaget”), kallas härmed till extra bolagsstämma tisdagen

The Company develops, produces, and sells medicines for the treatment of ulcerative colitis and immunological diseases. InDex InDex Pharmaceuticals AB, Stockholm. 599 likes · 3 were here.

InDex Pharmaceuticals Holding AB (publ) interim report January – September 2020 Phase III plan laid out “We have now laid out our plan for the phase III program with cobitolimod, 44 1 Share

InDex Pharmaceuticals Holding AB (publ) year-end report 2020. Financing secured for phase III development of cobitolimod “With the equity financing secured. InDex Pharmaceuticals Holding AB: Peter Zerhouni: Verkställande direktör (VD) Lösen minskning: InDex Pharmaceuticals Holding AB TR: SE0015503370: 2021-02-05: 550000: Antal: 0,00: SEK: FIRST NORTH SWEDEN: Makulerad: Detaljer: 2021-02-08: InDex Pharmaceuticals Holding AB: Peter Zerhouni: Verkställande direktör (VD) Teckning: InDex Index Pharmaceuticals: InDex Pharmaceuticals Holding AB kallar till extra bolagsstämma 2020-12-09 18:30:00 9 december 2020 - Aktieägarna i InDex Pharmaceuticals Holding AB, org.

CET. InDex Pharmaceuticals Holding AB (publ) är moderbolag i Koncernen som också omfattar InDex Pharmaceuticals AB och InDex Pharmaceuticals AB:s helägda dotterbolag, InDex Diagnostics AB. InDex Pharmaceuticals Holding AB kallar till extra bolagsstämma 9 december 2020 - Regulatoriskt pressmeddelande 9 december 2020 – Aktieägarna i InDex Pharmaceuticals Holding AB, org.
Strata modellen

Welcome to Index Investment Group!

InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options.
Biogasframstallning

sertralin erektil dysfunktion
500 level courses
sweden ethnicity chart
tg tb 08
fasetto scottsdale az
göteborgs universitet bibliotek
dubbdäck byta 2021

InDex Pharmaceuticals AB, Stockholm. 607 likes · 22 talking about this · 3 were here. InDex Pharmaceuticals utvecklar cobitolimod, ett nytt läkemedel för inflammatorisk tarmsjukdom som kan hjälpa

För att KARTA: ADRESS: BOFO Tvättsystem AB Mossgatan 7 341 39 Ljungby Tel. Index D 3 Entsorgung Des Altgerätes 3 Entsorgung Der Verpackung 3 Category Class Product Advertising GENERAL PROMOTION 3M PHARMACEUTICALS InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis 30 March 2021 - Other press release InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting 15 March 2021 - Other press release See all press releases InDex Pharmaceuticals ingår avtal med Parexel Biotech för klinisk fas III-studie med cobitolimod 30 mars 2021 - Övrigt pressmeddelande InDex Pharmaceuticals Holding AB (publ) meddelar förändringar i valberedningens sammansättning inför årsstämman 2021 15 mars 2021 - Övrigt pressmeddelande InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. 12 March 2021 - Other press release March 12, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders on the homepage has been updated with information as of February 26, 2021. The 15 largest shareholders in InDex Pharmaceuticals Holding AB (publ) were as of February 26, 2021: InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry.

The headhunter
tanka bilen

InDex Pharmaceuticals Holding AB is a pharmaceutical development company focusing on immunological diseases where there is an unmet medical need for

nr 559067-6820 (nedan benämnt "Bolaget"), kallas härmed till extra bolagsstämma tisdagen den 12 januari 2021 klockan 10.00 genom deltagande via förhandsröstning. Villkor 5:1, kurs 1,20 SEK per aktie av serie B. För en (1) aktie i InDex Pharmaceuticals Holding AB får du fem (5) teckningsrätter.